Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats

Cardiovascular Drugs and Therapy

Volumn 28, Issue 2, 2014, Pages 145-161

  Jennings, Brett L ^a   Montanez, David E ^a   May, Michael E ^a   Estes, Anne M ^a   Fang, Xiao R ^a   Yaghini, Fariborz A ^a   Kanu, Alie ^b   Malik, Kafait U ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

2,4,3 ,5 tetramethoxystilbene; Cytochrome P450 1B1; Inflammation; Oxidative stress; Spontaneously hypertensive rat

Indexed keywords

CATECHOLAMINE; CYTOCHROME P450 1B1; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ELEVATED BLOOD PRESSURE; ENZYME ACTIVITY; HEART MUSCLE FIBROSIS; KIDNEY DISEASE; NONHUMAN; ONCOGENE SRC; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC TONE; WISTAR KYOTO RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CATECHOLAMINES; CYTOKINES; ENDOTHELIUM, VASCULAR; FIBROSIS; GENES, SRC; HYDROGEN PEROXIDE; HYPERTENSION; HYPERTROPHY; KIDNEY; KIDNEY DISEASES; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH; NADPH OXIDASE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REACTIVE OXYGEN SPECIES; STILBENES; SUPEROXIDES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84897057898     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6510-4     Document Type: Article

References (55)

1. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947-60.
2. Jennings BL, Sahan-Firat S, Estes AM, et al. Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology. Hypertension. 2010;56:667-74.
3. Sahan-Firat S, Jennings BL, Yaghini FA, et al. 2,3′,4,5′- Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1. Am J Physiol Heart Circ Physiol. 2010;299:H1891-901.
4. Jennings BL, Estes AM, Anderson LJ, et al. Cytochrome P450 1B1 gene disruption minimizes deoxycorticosterone acetate-salt-induced hypertension and associated cardiac dysfunction and renal damage in mice. Hypertension. 2012;60:1510-6.
5. White K, Johansen AK, Nilsen M, et al. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation. 2012;126:1087-98.
6. Yaghini FA, Song CY, Lavrentyev EN, et al. Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation. Hypertension. 2010;55:1461-7.
7. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132-40.
8. Harwani SC, Chapleau MW, Legge KL, Ballas ZK, Abboud FM. Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension. Circ Res. 2012;111:1190-7.
9. Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol. 2004;287:H695-703.
10. Jennings BL, Anderson LJ, Estes AM, et al. Involvement of cytochrome P-450 1B1 in renal dysfunction, injury, and inflammation associated with angiotensin II-induced hypertension in rats. Am J Physiol Renal Physiol. 2012;302:F408-20.
11. Jennings BL, Anderson LJ, Estes AM, et al. Cytochrome P450 1B1 contributes to renal dysfunction and damage caused by angiotensin II in mice. Hypertension. 2012;59:348-54.
12. Chun Y-J, Kim S, Kim D, Lee S-K, Guengerich FP. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 2001;61:8164-70.
13. Yaghini FA, Li F, Malik KU. Expression and mechanism of spleen tyrosine kinase activation by angiotensin II and its implication in protein synthesis in rat vascular smooth muscle cells. J Biol Chem. 2007;282:16878-90.
14. Dobrowolski L, Walkowska A, Kompanowska-Jezierske E, Kuczeriszka M, Sadowski A. Effects of ATP on rat renal haemodynamics and excretion: Role of sodium intake, nitric oxide and cytochrome P450. Acta Phsyiol. 2007;189:77-85.
15. Zhao W, Ahokas RA, Weber KT, Sun Y. ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am J Phsyiol Heart Circ Physiol. 2006;291:H336-43.
16. 1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension. 2003;42:1183-90.
17. Miller Jr FJ, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res. 1998;82:1298-305.
18. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2006;103:7432-7.
19. Fan YY, Kohno M, Nakano D, et al. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. J Hypertens. 2010;28:1034-43.
20. Mefford IN. Biomedical uses of high-performance liquid chromatography with electrochemical detection. Methods Biochem Anal. 1985;31:221-58.
21. Warshaw DM, Mulvany MJ, Halpern W. Mechanical and morphological properties of arterial resistance vessels in young and old spontaneously hypertensive rats. Circ Res. 1979;45:250-9.
22. Collis MG, DeMey C, Vanhoutte PM. Renal vascular reactivity in the young spontaneously hypertensive rat. Hypertension. 1980;2:45-52.
23. Berecek KH, Stocker M, Gross F. Changes in renal vascular reactivity at various stages of deoxycorticosterone hypertension in rats. Circ Res. 1980;46:619-24.
24. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. New Eng J Med. 1990;323:22-7.
25. Vapaatalo H, Mervaala E, Nurminen M-L. Role of endothelium and nitric oxide in experimental hypertension. Physiol Res. 2000;49:1-10.
26. Rettig R, Folberth C, Stauss H, Kopf D, Waldherr R, Unger T. Role of the kidney in primary hypertension: a renal transplantation study. Am J Physiol Renal Physiol. 1990;258:F606-11.
27. Hultström M. Development of structural kidney damage in spontaneously hypertensive rats. J Hypertens. 2012;30:1087-91.
28. Hall JE, Granger JP, de Carmo JM, et al. Hypertension: physiology and pathophysiology. Compr Physiol. 2012;2:2393-442.
29. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension. Diabetes Care. 2008;31:S170-80.
30. Nistala R, Whaley-Connell A, Sowers JR. Redox control of renal function and hypertension. Antioxid Redox Signal. 2008;10:2047-89.
31. Datla SR, Griendling KK. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension. 2010;56:325-30.
32. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-97.
33. Bolterman RJ, Manriquez MC, Ruiz MCO, Juncos LA, Romero JC. Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats. Hypertension. 2005;46:943-7.
34. Vaziri ND, Ni Z, Oveisi F. Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension. 1998;31:1248-54.
35. Vaziri ND, Ni Z, Oveisi F, Trnavsky-Hobbs DL. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension. 2000;36:957-64.
36. Ülker S, McMaster D, McKeown PP, Bayraktutan U. Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc Res. 2003;59:488-500.
37. Akpaffiong MJ, Taylor AA. Antihypertensive and vasodilator actions of antioxidants in spontaneously hypertensive rats. Am J Hypertens. 1998;11:1450-60.
38. Monroy-Ruiz J, Sevilla M-Á, Carrón R, Montero M-J. Astaxanthin-enriched-diet reduces blood pressure and improves cardiovascular parameters in spontaneously hypertensive rats. Pharmacol Res. 2011;63:44-50.
39. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension. 2001;38:606-11.
40. Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res. 1998;39:77-88.
41. Wang H, Yang Y-J, Qian H-Y, Zhang Q, Xu H, Li J-J. Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev. 2012;17:437-48.
42. Chen Z-H, Hurh Y-J, Na H-K, et al. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis. 2004;25:2005-13.
43. Rush JWE, Quadrilatero J, Levy AS, Ford RJ. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp Biol Med. 2007;232:814-22.
44. López-Sepúlveda R, Jiménez R, Romero M, et al. Wine polyphenols improve endothelial function in large vessels of female spontaneously hypertensive rats. Hypertension. 2008;51:1088-95.
45. Thandapilly SJ, Wojciechowski P, Behbahani J, et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens. 2010;23:192-6.
46. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol. 2011;667:258-64.
47. Abboud FM. The sympathetic system in hypertension. State-of-the-art review Hypertension. 1982;4:II208-25.
48. Grisk O, Rettig R. Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc Res. 2004;61:238-46.
49. Pascual DW, Jin H, Bost KL, Oparil S. Interleukin-2 does not attenuate hypertension in spontaneously hypertensive rats. Hypertension. 1990;16:468-71.
50. Tuttle RS, Boppana DP. Antihypertensive effect of interleukin-2. Hypertension. 1990;15:89-94.
51. Dzielak DJ. Interleukin-2 and spontaneous hypertension. Hypertension. 1991;18:171-5.
52. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003;14:361-8.
53. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res. 2006;71:247-58.
54. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1B1. Drug Metab Dispos. 2004;32:840-7.
55. Son Y, Cheong Y-K, Kim N-H, Chung H-T, Kang DG, Pae H-O. Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways? J Signal Transduct. 2011. doi: 10.1155/2011/792639.